口腔黏膜病和口腔症状与炎症性肠病的相关性研究

doi:10.13701/j.cnki.kqyxyj.2020.04.019

口腔医学研究 ›› 2020, Vol. 36 ›› Issue (4): 387-392.DOI: 10.13701/j.cnki.kqyxyj.2020.04.019

• 牙周病学与黏膜病学研究 • 上一篇下一篇

口腔黏膜病和口腔症状与炎症性肠病的相关性研究

张丽敏¹, 周家敏¹, 张涵¹, 陆云洋², 魏晓渝², 张馨方², 陈白莉^3*, 杨军英^1*

1.中山大学附属第一医院口腔科广东广州 510080;
2.中山大学附属口腔医院,光华口腔医学院广东广州 510055;
3.中山大学附属第一医院消化内科广东广州 510080

收稿日期:2019-07-18 出版日期:2020-05-28 发布日期:2020-05-28
通讯作者: 陈白莉,E-mail:chenbaili05@163.com; 杨军英,E-mail:aliceyang2006@126.com
作者简介:张丽敏(1993~ ),女,安徽阜阳人,硕士在读,主要从事口腔内科学研究。
基金资助:
2018年国家级大学生创新训练计划项目(编号:201801150)

Study on Association between Oral Mucosal Diseases, Oral Symptoms, and Inflammatory Bowel Disease

ZHANG Limin¹, ZHOU Jiamin¹, ZHANG Han¹, LU Yunyang², WEI Xiaoyu², ZHANG Xinfang², CHEN Baili^3*, YANG Junying^1*

1. Department of Stomatology, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China;
2. Guanghua School of Stomatology, Hospital of Stomatology, Sun Yat-sen University, Guangzhou 510055, China;
3. Department of Gastroenterology, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China

Received:2019-07-18 Online:2020-05-28 Published:2020-05-28

摘要/Abstract

摘要： 目的: 研究炎症性肠病(inflammatory bowel disease,IBD)的活动性、病程、用药类型与口腔黏膜病和口腔症状的关系。方法: 采用横断面研究对389例IBD患者[265例克罗恩病(CD组)和124例溃疡性结肠炎(UC组)]和265例健康者(对照组)进行问卷调查和口腔黏膜检查。数据分析运用χ²检验和Logistic回归。结果: CD组沟纹舌的患病率比对照组增加(P=0.021),其患病风险增加7.76倍。相比对照组,CD和UC组口干和口腔异味的发生率均明显增加(P<0.05),口干的发生风险分别增加1.98倍和1.48倍,口腔异味的发生风险分别增加0.96倍和0.72倍。活动期CD患者复发性阿弗他溃疡和沟纹舌的患病率比缓解期者增加(P=0.048,P=0.009)。口腔扁平苔藓的患病率随CD病程的延长而增加(P=0.035)。CD组中应用氨基水杨酸制剂者口腔黏膜异常检出率比免疫抑制剂者增加(P=0.003)。结论: IBD患者口腔黏膜病的患病风险和口腔症状的发生风险增加,并与IBD的活动性、病程、用药类型相关,亟需口腔卫生宣教和多学科综合治疗。

关键词: 口腔黏膜病, 口腔症状, 炎症性肠病, 克罗恩病, 溃疡性结肠炎

Abstract: Objective: To study the association between activity, duration, and drug therapy of inflammatory bowel disease (IBD) and oral mucosal diseases and oral symptoms. Methods: In this cross-sectional study, questionnaires and oral mucosal examinations were conducted among 389 IBD patients [265 with Crohn’s disease (CD) and 124 with ulcerative colitis (UC)] and 265 healthy controls. Chi-square tests and logistic regression were used to analyse the data. Results: The prevalence of fissured tongue in CD patients was higher than controls (P=0.021), and the risk increased by 7.76 times. Compared with controls, CD and UC patients had higher incidence of xerostomia and halitosis (P<0.05), and the risk of xerostomia increased by 1.98 times and 1.48 times, respectively, and the risk of halitosis increased by 0.96 times and 0.72 times, respectively. Active CD had higher prevalence of recurrent aphthous ulcer and fissured tongue compared with that in remission (P=0.048, P=0.009). The prevalence of oral lichen planus increased over the duration of CD patients (P=0.035). The detection rate of abnormal oral mucosa in CD patients treated with aminosalicylate was higher than that in immunosuppressive patients (P=0.003). Conclusion: Patients with IBD have higher risk of oral mucosal diseases and oral symptoms, which are associated with IBD activity, duration, and drug therapy, and require oral health education and multidisciplinary treatment

Key words: oral mucosal disease, oral symptom, inflammatory bowel disease, Crohn’s disease, ulcerative colitis

张丽敏, 周家敏, 张涵, 陆云洋, 魏晓渝, 张馨方, 陈白莉, 杨军英. 口腔黏膜病和口腔症状与炎症性肠病的相关性研究[J]. 口腔医学研究, 2020, 36(4): 387-392.

ZHANG Limin, ZHOU Jiamin, ZHANG Han, LU Yunyang, WEI Xiaoyu, ZHANG Xinfang, CHEN Baili, YANG Junying. Study on Association between Oral Mucosal Diseases, Oral Symptoms, and Inflammatory Bowel Disease[J]. Journal of Oral Science Research, 2020, 36(4): 387-392.

参考文献

[1] Kamm MA. Rapid changes in epidemiology of inflammatory bowel disease[J]. Lancet, 2018,390(10114):2741-2742.
[2] Vavricka SR, Schoepfer A, Scharl M, et al. Extraintestinal manifestations of inflammatory bowel disease[J]. Inflamm Bowel Dis, 2015, 21(8):1982-1992.
[3] Lauritano D, Boccalari E, Stasio DD, et al. Prevalence of oral lesions and correlation with intestinal symptoms of inflammatory bowel disease: A systematic review[J]. Diagnostics (Basel), 2019, 9(3):77-92.
[4] Gomollón F, Dignass A, Annese V, et al. Third European evidence-based consensus on the diagnosis and management of Crohn’s disease 2016. Part 1: diagnosis and medical management[J]. J Crohns Colitis, 2016, 11(1):3-25.
[5] Magro F, Gionchetti P, Eliakim R, et al. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. part 1: definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and Ileo-anal pouch disorders[J]. J Crohns Colitis, 2017, 11(6):649-670.
[6] Yeung CA. Oral health surveys: Basic methods[M]. 5th edition.British Dental Journal, 2014.
[7] 陈谦明. 口腔黏膜病学[M]. 北京: 人民卫生出版社, 2012.
[8] 王红梅, 乔树芳. 增殖性化脓性口炎[J]. 国际口腔医学杂志, 2013,40(6):826-828.
[9] Rautava J, Pinnell LJ, Vong L, et al. Oral microbiome composition changes in mouse models of colitis[J]. J Gastroenterol Hepatol, 2015, 30(3):521-527.
[10] Nakajima M, Arimatsu K, Kato T, et al. Oral administration of P. gingivalis induces dysbiosis of gut microbiota and impaired barrier function leading to dissemination of enterobacteria to the liver[J]. PLoS One, 2015,10(7):e0134234.
[11] Muhvi-Urek M, Tomac-Stojmenović M, MijandruŠi-Sini B. Oral pathology in inflammatory bowel disease[J]. World J Gastroenterol, 2016, 22(25):5655-5667.
[12] de Vries S, Tan C, Bouma G, et al. Salivary function and oral health problems in Crohn's disease patients[J]. Inflamm Bowel Dis, 2018, 24(6):1361-1367.
[13] Gjuladin-Hellon T, Gordon M, Iheozor-Ejiofor Z, et al. Oral 5-aminosalicylic acid for maintenance of surgically-induced remission in Crohn's disease[J]. Cochrane Database Syst Rev, 2019, 6(6):CD008414.
[14] Curkovic I, Egbring M, Kullak-Ublick GA. Risks of inflammatory bowel disease treatment with glucocorticosteroids and aminosalicylates[J]. Dig Dis, 2013, 31(3-4):368-373.
[15] Li X, Song P, Li J, et al. The disease burden and clinical characteristics of inflammatory bowel disease in the Chinese population: A systematic review and meta-analysis[J]. Int J Environ Res Public Health, 2017,14(3):238-249.
[16] Laranjeira N, Fonseca J, Meira T, et al. Oral mucosa lesions and oral symptoms in inflammatory bowel disease patients[J]. Arq Gastroenterol, 2015, 52(2):105-110.
[17] Elahi M, Telkabadi M, Samadi V, et al. Association of oral manifestations with ulcerative colitis[J]. Gastroenterol Hepatol Bed Bench, 2012, 5(3):155-160.
[18] Brito F, de Barros FC, Zaltman C, et al. Prevalence of periodontitis and DMFT index in patients with Crohn's disease and ulcerative colitis[J]. J Clin Periodontol, 2008, 35(6):555-560.
[19] Grössner-Schreiber B, Fetter T, Hedderich J, et al. Prevalence of dental caries and periodontal disease in patients with inflammatory bowel disease: a case-control study[J]. J Clin Periodontol, 2006, 33(7):478-484.
[20] Mortada I, Leone A, Gerges GA, et al. Oral manifestations of inflammatory bowel disease[J]. J Biol Regul Homeost Agents, 2017, 31(3):817-821.
[21] Katz J, Shenkman A, Stavropoulos F, et al. Oral signs and symptoms in relation to disease activity and site of involvement in patients with inflammatory bowel disease[J]. Oral Dis, 2003, 9(1):34-40.
[22] Szymanska S, Lördal M, Rathnayake N, et al. Dental caries, prevalence and risk factors in patients with Crohn's disease[J]. PLoS One, 2014, 9(3):e91059.
[23] 董子昱, 张芳. 口腔扁平苔藓唾液标记物研究现状分析[J]. 口腔医学研究, 2018, 34(11):1168-1171.
[24] Kumar KM, Nachiammai N, Madhushankari GS. Association of oral manifestations in ulcerative colitis: A pilot study[J]. J Oral Maxillofac Pathol, 2018, 22(2):199-203.
[25] Singh S, Stroud AM, Holubar SD, et al. Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis[J]. Cochrane Database Syst Rev, 2015, 11(11): CD001176.

口腔黏膜病和口腔症状与炎症性肠病的相关性研究

Study on Association between Oral Mucosal Diseases, Oral Symptoms, and Inflammatory Bowel Disease

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 1

编辑推荐

Metrics